HAEM5:Hepatosplenic T-cell lymphoma - Revision history

Sumire.Kitahara at 04:08, 7 January 2026

2026-01-07T04:08:53Z

← Older revision		Revision as of 23:08, 6 January 2026
Line 1:		Line 1:
	~~{{DISPLAYTITLE:Hepatosplenic T-cell lymphoma}}~~

	==Primary Author(s)*==		==Primary Author(s)*==
	Forough Sargolzaeiaval, MD		Forough Sargolzaeiaval, MD

Sumire.Kitahara: /* Gene Rearrangements */

2026-01-07T02:06:22Z

Gene Rearrangements

Show changes

Forough.Sargolzaeiaval: /* Individual Region Genomic Gain/Loss/LOH */

2025-12-10T06:00:21Z

Individual Region Genomic Gain/Loss/LOH

Show changes

Forough.Sargolzaeiaval: /* Individual Region Genomic Gain/Loss/LOH */

2025-11-24T07:08:11Z

Individual Region Genomic Gain/Loss/LOH

Show changes

Bailey.Glen at 17:16, 3 July 2025

2025-07-03T17:16:17Z

@@ Line 27: / Line 27: @@
 |Hepatosplenic T-cell lymphoma
 |}
 ==Related Terminology==

Bailey.Glen at 21:35, 25 May 2025

2025-05-25T21:35:45Z

← Older revision		Revision as of 16:35, 25 May 2025
Line 77:		Line 77:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 187:		Line 187:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 258:		Line 258:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 302:		Line 302:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~<ref name=":4" />		!Diagnostic Significance (Yes, No or Unknown)<ref name=":4" />
	!Prognostic Significance (Yes, No or Unknown)<ref name=":2" /><ref name=":4" />		!Prognostic Significance (Yes, No or Unknown)<ref name=":2" /><ref name=":4" />
	!Therapeutic Significance (Yes, No or Unknown)<ref name=":2" /><ref>{{Cite journal\|last=Pro\|first=Barbara\|last2=Allen\|first2=Pamela\|last3=Behdad\|first3=Amir\|date=2020-10-29\|title=Hepatosplenic T-cell lymphoma: a rare but challenging entity\|url=https://pubmed.ncbi.nlm.nih.gov/32756940\|journal=Blood\|volume=136\|issue=18\|pages=2018–2026\|doi=10.1182/blood.2019004118\|issn=1528-0020\|pmc=7596851\|pmid=32756940}}</ref>		!Therapeutic Significance (Yes, No or Unknown)<ref name=":2" /><ref>{{Cite journal\|last=Pro\|first=Barbara\|last2=Allen\|first2=Pamela\|last3=Behdad\|first3=Amir\|date=2020-10-29\|title=Hepatosplenic T-cell lymphoma: a rare but challenging entity\|url=https://pubmed.ncbi.nlm.nih.gov/32756940\|journal=Blood\|volume=136\|issue=18\|pages=2018–2026\|doi=10.1182/blood.2019004118\|issn=1528-0020\|pmc=7596851\|pmid=32756940}}</ref>

Bailey.Glen at 20:12, 25 May 2025

2025-05-25T20:12:05Z

← Older revision		Revision as of 15:12, 25 May 2025
Line 42:		Line 42:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Erythrophagocytic Tγ lymphoma
	\|}		\|}

Bailey.Glen at 17:37, 24 March 2025

2025-03-24T17:37:40Z

← Older revision		Revision as of 12:37, 24 March 2025
Line 5:		Line 5:
	*Forough Sargolzaeiaval, MD		*Forough Sargolzaeiaval, MD
	*Michelle Don, MD, MS		*Michelle Don, MD, MS
	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Jennelleh: /* Gene Rearrangements */

2025-02-19T08:37:13Z

Gene Rearrangements

← Older revision		Revision as of 03:37, 19 February 2025
Line 65:		Line 65:
	!Clinical Relevance Details/Other Notes		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|		\|N/A
	\|		\|
	\|		\|
Line 532:		Line 532:
	The <u>morphologic features</u> of this disease are detailed below:		The <u>morphologic features</u> of this disease are detailed below:

	* Typically shows a sinusoidal pattern		*Typically shows a sinusoidal pattern

	The <u>immunophenotype</u> of this disease is detailed below:		The <u>immunophenotype</u> of this disease is detailed below:

Jennelleh at 08:35, 19 February 2025

2025-02-19T08:35:59Z

@@ Line 27: / Line 27: @@
 |Subtype(s)
 |Hepatosplenic T-cell lymphoma
 |}
 ==WHO Essential and Desirable Genetic Diagnostic Criteria==
@@ Line 187: / Line 131: @@
 |-
 !Chr #!!Gain / Loss / Amp / LOH!!Minimal Region Genomic Coordinates [Genome Build]!!Minimal Region Cytoband
-!Diagnostic Significance (Yes, No or Unknown)<ref name=":2" /><ref name=":4">McKinney, M., Moffitt, A.B., Gaulard, P., Travert, M., De Leval, L., Nicolae, A., Raffeld, M., Jaffe, E.S., Pittaluga, S., Xi, L. and Heavican, T., 2017. The genetic basis of hepatosplenic T-cell lymphoma. ''Cancer discovery'', ''7''(4), pp.369-379.</ref>
+!Diagnostic Significance (Yes, No or Unknown)<ref name=":2">Yabe M, Miranda RN, Medeiros LJ. Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. ''Hum Pathol''. 2018;74:5‐16. doi:10.1016/j.humpath.2018.01.005</ref><ref name=":4">McKinney, M., Moffitt, A.B., Gaulard, P., Travert, M., De Leval, L., Nicolae, A., Raffeld, M., Jaffe, E.S., Pittaluga, S., Xi, L. and Heavican, T., 2017. The genetic basis of hepatosplenic T-cell lymphoma. ''Cancer discovery'', ''7''(4), pp.369-379.</ref>
 !Prognostic Significance (Yes, No or Unknown)<ref name=":2" /><ref name=":4" />
 !Therapeutic Significance (Yes, No or Unknown)
@@ Line 200: / Line 144: @@
 |Yes
 |No
-|Considered a primary aberration<ref name=":2" />, seen in 40-70% of cases<ref name=":1" />
+|Considered a primary aberration<ref name=":2" />, seen in 40-70% of cases<ref name=":1">{{Cite journal|title=Hepatosplenic T-cell lymphoma. In: WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]|url=https://tumourclassification.iarc.who.int/chaptercontent/63/229|displayauthors=1|last=Medeiros|first=Jeffrey|date=2024|journal=WHO classification of tumours series, 5th ed.|volume=vol. 11|pages=|via=Lyon (France): International Agency for Research on Cancer}}</ref>
 |-
 |8
@@ Line 560: / Line 504: @@
 ==Additional Information==
-*N/A
+* Typically shows a sinusoidal pattern
 ==Links==